GlassScriptPhysician profile
Barbara J Conlon
NPI 1558352823
$3,660.79
in general payments reported to CMS, 2019-2025
26 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $672 · 2023: $625 · 2024: $857 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.21 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $767.94 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $347.94 | 2021-2025 | |
| Novo Nordisk INC | $307.77 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $281.06 | 2021-2024 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $189.52 | 2021-2025 | Nexletol |
| Shockwave Medical, INC | $181.55 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $136.00 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.12 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $128.52 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $125.85 | 2022-2025 | Verquvo |
| Ionis Pharmaceuticals, INC. | $125.18 | 2025 | Tryngolza |
| Heartflow, INC. | $123.72 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.13 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.65 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $89.28 | 2023-2025 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $70.80 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $68.91 | 2021-2023 | Xarelto |
| Abbott Laboratories | $68.04 | 2021-2023 | Cardiomems |
| Inspire Medical Systems, INC. | $57.89 | 2024 | Inspire |
| Chiesi USA, INC. | $49.38 | 2025 | Juxtapid |
| Astrazeneca Pharmaceuticals LP | $44.43 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $41.74 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $41.24 | 2022-2025 | Evkeeza, Praluent |
| Actelion Pharmaceuticals US, INC. | $37.37 | 2024-2025 | Uptravi, Opsumit |
| Sobi, INC | $25.02 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.74 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Conlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.